GENE ONLINE|News &
Opinion
Blog

Jennifer Doudna
Funding
Jennifer Doudna’s Gene Editing Firm Mammoth Biosciences Attains Unicorn Status
2021-09-11
Funding Cas9
Scribe Therapeutics Bags $100 Million in Series B to Advance CRISPR-Based Therapies
2021-04-01
R&D
AbbVie Signs Off-the-Shelf CAR-T Therapy Pact with Jennifer Doudna’s Caribou Biosciences
2021-02-11
Technology
The Future of CRISPR: Three Areas The Nobel Prize Winning Tech Will Be Most Impactful
2020-10-25
Technology Cas9
New Cas9 Alternatives Give Mammoth Biosciences an Edge Over Other CRISPR companies
2020-10-25
Technology Cas9
CRISPR Pioneers Bag 2020 Nobel Prize in Chemistry
2020-10-07
R&D CRISPR
Mammoth Biosciences Signs Deal with UC Berkeley for Novel Micro CRISPR Protein
2020-08-16
Technology Cas9
Spotlight: New Hypercompact Megaphage Cas Enzyme (CasΦ) Shows Efficient Gene Editing
2020-08-16
Technology
Evolved Base Editor Surpasses Predecessors with High Efficiency and Versatility
2020-03-18
Technology Cas9
Jennifer Doudna Cofounded Mammoth Biosciences Bags $45M for CRISPR Based Diagnostics
2020-02-01
Technology CRISPR
CRISPR Scientists Receive 2020 Wolf Prize in Medicine
2020-01-15
Ranking & Reports CRISPR
Top 5 News from the World of CRISPR Gene Editing
2019-04-26
Technology CRISPR
CRISPR Scientists Seek a Moratorium on Heritable Genome Editing
2019-03-15
CRISPR Babies
The Scientists Strongly Condemned for the First Gene Editing Baby’s Birth in China
2018-11-27
Technology CRISPR
The Pioneer of CRISPR Genome Editing ─ Jennifer A. Doudna Visits Taiwan
2018-11-25
1 2
LATEST
Core8 Group and MedArmor to Pioneer Vietnam’s First AI x ESG Hospital
2024-12-10
The Future of Generative AI for New Drug Development and Precision Medicine
2024-12-09
How FIRM is Shaping Regenerative Medicine in Japan
2024-12-09
AI, Smart Tech, and ICT to Unite the Global Biotech and Healthcare Industries in 2025
2024-12-06
Core8 Group to Establish Vietnam’s First Comprehensive Biotechnology Incubator
2024-12-05
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
2024-12-05
Ipsen Bets $600M on Biomunex’s First-in-Class T-Cell Engager BMX-502
2024-12-03
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top